 |
[email protected] |
 |
3275638434 |
 |
 |
| Paper Publishing WeChat |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Stephen Olaribigbe Majekodunmi and Cynthia Chibuzor Uzoaganobi
Full-Text PDF
XML 993 Views
DOI:10.17265/1934-7375/2017.02.005
Commercially available domperidone -a D2 receptor antagonist- is an immediate release formulation which has never been formulated into microspheres for sustained release. The present work aims towards studying the effect of combination of a natural chitosan from an oyster shell of Mystilis edulis and HPMC (hydroxy propyl methyl cellulose) (spectracel 15 E) as polymer and tripolyphosphate as cross linking agent using wet gelation technique. The various polymer combination ratios for different batches were compared with a low molecular weight standard chitosan. The extracted chitosan – HPMC polymer combination ratios were chosen at ten levels: as batches B1, B2, B3, B4, B5, B6, B7, B8, B9, B10 for 1:1, 1:2, 2:1, 1:0, 0:1, 3:1, 1:3, 5:1, and 1:5 and 1:1 having 450:450, 300:600, 600:300, 900:0, 0:900, 675:225, 225:675, 750:150, 150:750, 450:450 mg respectively, while the quantity of domperidone and tripolyphosphate remained constant. B11 and B12 were formulated with standard chitosan and HPMC. The percentage yield of the formulated microspheres was determined and then evaluated for flowability, drug entrapment efficiency, drug release and mechanism of drug release by Fickian diffusion. The best batches of the domperidone loaded microspheres produced from the combination polymer were compared with the standard chitosan. The highest yields of microspheres were given by batches B12, B11, B10, and B4 with values of 50.1 ± 0.1%, 49.6 ± 0.1%, 46.6 ± 0.1%, and 46.1 ± 0.0% respectively while the lowest yield were 23.3 ± 0.2% and 23.6 ± 0.2%. B5 and B6 and B9 did not yield any microsphere. The bulk density, tapped density, compressibility and Hausner’s ratio of the microspheres showed good flowability and high percent compressibility. The drug entrapment efficiency showed that the entrapment ranged from 54.2 to 97.2, where the least entrapment was B4 (54.2 ± 0.1) and the highest B12 (97.2 ± 0.2). The polymer surface of the microspheres as observed by SEM (scanning electron microscopy) was heterogeneous and porous which offers enhanced bioadhesivity. The dissolution study was used to determine the percentage drug release which ranged from 12.1% to 68.9% after 5 hours. Batches 1, 2, 3, 4, 7, and 11 follow zero order kinetics via Fickian diffusion. The results indicate that microspheres of domperidone could be successfully formulated with a natural chitosan either alone or in combination with HPMC for sustained delivery of domperidone. Furthermore, the concentration of the natural polymer and HPMC employed in the formulation need to be carefully selected to enable the production of microspheres with the desired sustained release properties.
Domperidone, HPMC, polymer combination, microspheres, wet gelation technique
[1] Deshpande, S. S. 1995. “Structure-Digestibility Relationship of Legume 7s Proteins.” J. Food Sci. 54: 108-13.
[2] Guibal, E., Touraud, E., and Roussy, T. 2004. “Chitosan Interactions with Metal Ions and Dyes: Dissolved-state. Solid-state Applications.” World Journal of Microbioloical Biotechnology 21: 913.
[3] Williams, R., and Nicol, S. 1991. “Issues and Opportunities. Bureau of Rural Resources Proceedings 10. Bureau of Rural Resources and Australian Bureau of Agricultural.” In Australian and New Zealand Southern Trawl Fisheries Conference: Southern Ocean Resources, 207-15.
[4] Tolaimate, A., Desbrieres, J., Rhazi, M., Alagui, M., Vincendon, M., and Vottero, P. 2000. “The Influence of Deacetylation Process on the Physicochemical Characteristics of Chitosan from Squid Chitin.” Polymer 41: 2463-9.
[5] Kikkawa, T., Watanabe, Y., Katayama, Y., Kita, J., and Ishimatsu, A. 2008. “Acute CO2 Tolerance Limits of Juveniles of Three Marine Invertebrates, Sepia ly-cidas, Sepioteuthis Lessoniana, and Marsupenaeus Japonicus.” Plankton Benthos Res. 3: 184-7.
[6] Wang, Q., Liu, Y., and Yan, H. 2007. “Mechanism of a Self-templating Synthesis of Monodispersed Hollow Silica Nanospheres with Tunable Size and Shell Thick-ness.” Chem. Commun. 23: 2339-41.
[7] Kumar, M. N. V. R. 2000. “A Review of Chitin and Chitosan Applications.” Reactive & Functional Polymers (46): 1-27.
[8] Kataria, S., Middha, A., Sandhu, P., Ajay, B. and Bhawana, K. 2011. “Microsphere: A review.” International Journal of Research in Pharmacy and Chemistry 1 (4): 1184-98.
[9] Barone, J. A. 1999. “Domperidone: A Peripherally Acting Dopamine2-receptor Antagonist.” The Annals of Pharmacotherapy 33 (4): 429-40.
[10] Swann, I. L., Thompson, E. N., and Qureshi, K. 1979. “Domperidone or Metoclopramide in Preventing Chemotherapeutically Induced Nausea and Vomiting.” British Medical Journal 2 (6199):1188.
[11] Worthington, I., Pringsheim, T., Gawel, M. J., Gladstone, J., Cooper, P., Dilli, E., Aube, M., Leroux, E., and Becker, W. J. 2013. “Canadian Headache Society Guideline: Acute Drug Therapy for Migraine Headache.” The Canadian Journal of Neurological Sciences 40 (53): 356-67.
[12] Huang, W., Begum, R., Barber, T., Ibba, V., Tee, N., Hussain, M., Arastoo, M., Yang, Q., Robson, L., and Lesage, S. 2012. “Regenerative Potential of Silk Conduits in Repair of Peripheral Nerve Injury in Adult Rats.” Biomaterials 33: 59-71.
[13] Nishikaw, N., Nagai, M., Tsujii, T., Iwaki, H., Yabe, H., and Nomoto, M. 2012. “Co-administration of Domperidone Increases Plasma Levodopa Concentration in Patients with Parkinson Disease.” Clinical Neuropharmacology 35 (4): 182-4.
[14] Grzeskowiak, L. E., Lim, S. W., Thomas, A. E., Ritchie, U., and Gordon, A. L. 2013. “Audit of Domperidone Use as a Galactogogue at an Australian Tertiary Teaching Hospital.” Journal of Human Lactation 29 (1): 32-7.
[15] Donovan, M. J., Kim, S. H., Raman, V., and Smyth, H. D. 2012. “Dry Powder Inhaler Device Influence on Carrier Particle Performance.” J. of Pharm. Sci. 101 (3): 1097-107.
[16] Sakamoto, Y., Kato, S., Sekino, Y., Sakai, E, Uchiyama, T., Iida, H., Hosono, K., Endo, H., et al. 2011. “Effects of Domperidone on Gastric Emptying: A Crossover Study using a Continuous Real-time 13C Breath Test (Breath ID system).” Hepato-gastroenterology 58 (106): 637-41.
[17] Nagarsenker, M. S., Garad, S. D., and Ramprakash, G. 2000. “Design, Optimization and Evaluation of Domperidone Coevaporates.” Journal of Control Release 63: 31-9.
[18] Fishers, TechNote. 2001. Working with Microspheres 9025 Technology, www.bangslabs.com IN 46038-2886 800.387.0672.
[19] Sakamoto, Y., Kato, S., Sekino, Y., Sakai, E., Uchiyama, T., Iida, H., Hosono, K., Endo, H., et al. 2011. “Effects of Domperidone on Gastric Emptying: A Crossover Study Using a Continuous Real-Time 13C Breath Test (Breath ID system).” Hepato-Gastroenterology 58 (106): 637-41.
[20] Hemlata, G., Patil, R. T., Michael, A. R., and Kamalinder, K. S. 2011. “Formulation and Development of Orodispersible Sustained Release Tablet of Domperidone.” Journal of Pharmacy and Biomedical Sciences 34 (6): 246-56.
[21] Xiao, M., Qiu, X., Yue, D., Cai, Y., and Mo, Q. 2013. “Influence of Hippophaerhamnoides on Two Appetite Factors, Gastric Emptying and Metabolic Parameters, in Children with Functional Dyspepsia.” Hellenic Journal of Nuclear Medicine 16 (1): 38-43.
[22] Tiong, N., and Elkordy, A. A. 2009. “Effects of Liquisolid Formulations on Dissolution of Naproxen.” European Journal of Pharmacy and Biopharmacy 73: 373-84.
[23] Amidon, G. L., Lennernas, H., Shah, V. P., and Crison, J. R. 1995. “A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in-vitro Drug Product Dissolution and in-vivo Bioavailability.” Journal of Pharmaceutical Resources 12 (3): 413-20.
[24] Arun, M., and Mahale, S. A. 2013. “Sreenivas N. Development and Characterization of Diltiazem Hydrochloride Microspheres.” Journal of Pharmaceutical, Biological and Chemical Sciences 4 (2): 567-75.
[25] Dhankar, V. Garg, G, Dhamija, K., and Awasthi, R. 2014. “Preparation, Characterization and Evaluation of Ranitidine Hydrochloride-loaded Mucoadhesive Microspheres.” Polim Med. Apr-Jun 44 (2): 75-81.
[26] Jameela, S. R., and Jayakrishnan, A. 1995. “Glutaraldehydecrosslinked-chitosan Microspheres as a Long Acting Biodegradable Drug Delivery Vehicle:studies on the in-vitro Release of Mitoxantrone and in Vivo Degradation of Microspheres in Rat Muscle.” J. Control Rel. 16: 769-75.
[27] Shu, X. Z., and Zhu, K. J. 2000. “A Novel Approach to Prepare Tripolyphosphate/Chitosan Complex Beads for Controlled Drug Delivery.” Int. J. Pharm. 201: 51-8.
[28] Govender, S., Pillay, V., Chetty, D. J., and Essack, S. Y. 2005. “Optimization and Characterization of Bioadhesive Controlled Release Tetracycline Microspheres.” Int. J. Pharm. 306: 24-40.
[29] Kumbar, S. G., Kulkarni, A. R., and Aminabhavi, M. 2002. “Crosslinked Chitosan Microspheres for Encapsulation of Diclofenac Sodium: Effect of Crosslinking Agent.” J. Microencapsul 19 (2): 173-80.
[30] Vasir, J. K., Tambwekar, K., and Garg, S. 2003. “Bioadhesive Microspheres as a Controlled Drug Delivery System.” Int. J. Pharm 255:13-32.